- $258.13m
- $264.94m
- 25
- 42
- 24
- 20
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.37 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -27.9% | ||
Return on Equity | -45.95% | ||
Operating Margin | n/a |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
Directors
- Rene Sindlev CHM (59)
- Mark Dybul CEO (58)
- Luisa Puche CFO (58)
- Henrik Gronfeldt-Sorensen DRC (49)
- Gregg Alton IND (55)
- Carol Brosgart IND (70)
- Jayne McNicol IND (55)
- Carl Sandler IND (49)
- James Sapirstein IND (60)
- Last Annual
- June 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 18th, 2011
- Public Since
- November 18th, 2014
- No. of Shareholders
- 194
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market
- Shares in Issue
- 147,504,944
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- Century City Medical Plaza, LOS ANGELES, 90067
- Web
- https://renovarobio.com/
- Phone
- +1 2127630184
- Auditors
- Sadler, Gibb & Associates, LLC
Upcoming Events for RENB
Q4 2024 Renovaro Inc Earnings Release
Q1 2025 Renovaro Inc Earnings Release
Similar to RENB
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 22:56 UTC, shares in Renovaro are trading at $1.57. This share price information is delayed by 15 minutes.
Shares in Renovaro last closed at $1.57 and the price had moved by +149.17% over the past 365 days. In terms of relative price strength the Renovaro share price has outperformed the S&P500 Index by +98.27% over the past year.
There is no consensus recommendation for this security.
Renovaro does not currently pay a dividend.
Renovaro does not currently pay a dividend.
Renovaro does not currently pay a dividend.
To buy shares in Renovaro you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.57, shares in Renovaro had a market capitalisation of $231.58m.
Here are the trading details for Renovaro:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RENB
Based on an overall assessment of its quality, value and momentum Renovaro is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Renovaro. Over the past six months, its share price has underperformed the S&P500 Index by -57.79%.
As of the last closing price of $1.57, shares in Renovaro were trading -46.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Renovaro PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Renovaro's management team is headed by:
- Rene Sindlev - CHM
- Mark Dybul - CEO
- Luisa Puche - CFO
- Henrik Gronfeldt-Sorensen - DRC
- Gregg Alton - IND
- Carol Brosgart - IND
- Jayne McNicol - IND
- Carl Sandler - IND
- James Sapirstein - IND